Related Experiment Video
Updated: Jun 24, 2026

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan
Jun Horiguchi1, Yoshiaki Rai, Kazuo Tamura
1Breast and Endocrine Surgery, Gunma University Hospital, 3-39-15 Showa-Machi, Maebashi, Gunma 371-8511, Japan. junhorig@showa.gunma-u.ac.jp
Background:
The efficacy and safety of weekly paclitaxel was evaluated in Japanese women with advanced or metastatic breast cancer.
Patients And Methods:
Paclitaxel was given by single weekly intravenous infusion at 100 mg/m2 on days 1, 8, 15, 22, 29 and 36 of a 49-day cycle to women with advanced or metastatic breast cancer not responding to other chemotherapy.
Results:
A total of 69 enrolled patients received a median of 3 (range 1-13) cycles of treatment. The overall response rate was 44.9%, comprising 3 complete responses (CRs) and 28 partial responses (PRs). Median durations of CR and PR were 64.0 (range 57-499) and 113.0 (range 29-590) days, respectively. Grade 3 or greater adverse reactions included neutropenia in 37.7%, leukopenia in 31.9% and neuropathy in 5.8%.
Conclusion:
A weekly regimen of paclitaxel was well tolerated and achieved a relatively high response rate in Japanese breast cancer patients with advanced or metastatic disease.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Clinical Trials: Overview
